Nucleic acid based strategies as potential therapeutic tools: Mechanistic considerations and implications to restenosis

Journal of Molecular Medicine

Volumn 79, Issue 12, 2001, Pages 695-706

  Santiago, Fernando S ^a,b   Khachigian, Levon M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Antisense oligonucleotides; Catalytic DNA ribozymes; DNAzymes; Restenosis; Smooth muscle cells

Indexed keywords

ANGIOPEPTIN; ANGIOTENSIN; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBOCYTIC AGENT; CALPASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FATTY ACID; FIBROBLAST GROWTH FACTOR; GLUTATHIONE PEROXIDASE; HEPARIN DERIVATIVE; HYALURONIC ACID; HYPOTHALAMUS RELEASE INHIBITING FACTOR; INTEGRASE; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE DONOR; NUCLEIC ACID BASE; PLATELET DERIVED GROWTH FACTOR; POLOXAMER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PSORALEN; RECOMBINANT PROTEIN; RIBOZYME; SAPORIN; SOMATOMEDIN; STEM CELL FACTOR; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; VASCULOTROPIN;

BASE PAIRING; BIOENGINEERING; CELL GROWTH; DNA BINDING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; PHOTODYNAMIC THERAPY; RADIATION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ULTRASOUND THERAPY;

ANIMALS; BASE PAIRING; CORONARY RESTENOSIS; DNA; DNA, CATALYTIC; DNA, SINGLE-STRANDED; GENE EXPRESSION REGULATION; GENE TARGETING; HUMANS; MUSCLE, SMOOTH, VASCULAR; NUCLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA; RNA, CATALYTIC;

EID: 0035662558     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100272     Document Type: Review

References (99)

1. Signal transduction in arteriosclerosis: Mechanical stress-activated MAP kinases in vascular smooth muscle cells
2. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis
3. Cell cycle regulation and control of angioplasty restenosis
4. Restenosis after coronary angioplasty
5. Early growth response factor 1: A pleiotropic mediator of inducible gene expression
6. Antisense oligonucleotides: Promise and reality
7. Antisense oligodeoxynucleotide and ribo-zyme design
8. Identification and characterization of second-generation antisense oligonucleotides
9. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes
10. An antisense oligonucleotide primer
11. Selectivity of polyamines on the stability of RNA-DNA hybrids containing phosphodiester and phosphorothioate oligodeoxy-nucleotides
12. Polyamine effects on purine-purine-pyrimidine triple helix formation by phosphodiester and phosphorothioate oligodeoxynucleotides
13. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
14. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
15. Local delivery of c-myb antisense oligonucleotides during balloon angioplasty
16. Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts
17. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligonucleo-tides
18. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury
19. Anti-sense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries
20. Single intraluminal delivery of antisense cdc2 and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hy-perplasia
21. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
22. Effect of phosphorothioated oligonucleotides on neoin-tima formation in the rat carotid artery
23. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism
24. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury
25. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical?
26. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
27. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynu-cleotide
28. Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kB in vivo
29. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease
30. Role of AP-1 complex in angiotensin II-mediated transforming growth factor-B expression and growth of smooth muscle cells: Using decoy approach against AP-1 binding site
31. Novel negative regulatory element in the platelet-derived growth factor B chain promoter that mediates ERK-dependent transcriptional repression
32. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo
33. In vivo transfection of cis element "decoy" against nuclear factor-kB binding site prevents myocardial infarction
34. In vivo administration of a nuclear transcription factor-kB decoy suppresses experimental crescentric glomerulonephritis
35. Oligonucleotide-based gene therapy for cardiovascular disease
36. Ribozyme structures and mechanisms
37. Metal ions in ribozyme folding and catalysis
38. Structure, folding and catalysis of the small nucleolytic ribozymes
39. Hammerhead ribozyme design and application
40. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioa-tes
41. Correlation of activity with stability of chemically modified ribozymes in nuclei suspension
42. In vivo decay kinetic parameters of hammerhead rib-ozymes
43. Chemical modification of hammerhead ribozyme: Catalytic activity and nuclease resistance
44. Function and biological applications of catalytic nucleic acids
45. Rib-ozymes and the anti-gene therapy: How a catalytic RNA can be used to inhibit gene function
46. Inhibition of vascular smooth cell proliferation by ribozymes that cleave c-myb mRNA
47. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo
48. Ribozyme oligonucleotides against transforming growth factor-B inhibited neointimal formation after vascular injury in rat model
49. Direct transfer of transforming growth factor b1 gene into arteries stimulates fibrocellular hyperplasia
50. Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II
51. Role of transforming growth factor-beta 1 in the cellular response to angiotensin II
52. Angiotensin II-induced mito-genesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-b
53. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo
54. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduce s stent-induced stenosis in a porcine coronary model
55. Minimal sequence requirements for ribozyme activity
56. Using linkers to investigate the spatial separation of the conserved nucleotides A9 and G12 in the hammer-head ribozyme
57. In vit-ro activity of minimised hammerhead ribozymes
58. A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes
59. Nuclease-resistant chimeric ribozymes containing deoxyribonu-cleotides and phosphorothioate linkages
60. Hammerhead ribozymes: Importance of stem-loop II for activity
61. A minimised hammerhead ribozyme with activity against interluekin-2 in human cells
62. Hammerhead minizymes with high cleavage activity: A dimeric structure as the active conformation of minizymes
63. 2+ ions of the activities of dimeric hammerhead minizymes
64. CTAB-mediated enrichment of active forms of novel dimeric maxizymes
65. Catalytic activities of hammerhead ribozymes with a triterpen-oid linker instead of stem/loop II
66. Characterization of several kinds of dimer minizyme: Simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes
67. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression
68. A DNA enzyme that cleaves RNA
69. Characterization and divalent metal-ion dependence of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric oligonucleotides
70. Expanding the scope of RNA catalysis
71. A catalytic DNA for porphyrin metallation
72. Porphyrin metallation catalyzed by a small RNA molecule
73. DNA-enhanced peroxidase activity of a DNA aptamer-hemin complex
74. A general purpose RNA-cleaving DNA enzyme
75. Mechanism and utility of an RNA-cleaving DNA enzyme
76. Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity
77. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion
78. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the coreceptor function by DNA-enzyme
79. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme
80. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA
81. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)
82. Extreme high and specific activity of DNA enzymes in cells with a Philadelphia chromosome
83. Design of nuclease resistant protein kinase C-alpha DNA enzymes with potential therapeutic application
84. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme
85. New DNA enzyme targeting egr-1 mRNA inhibits vascular smooth muscle cell proliferation and regrowth after injury
86. A theoretical approach to select effective antisense oligode-oxyribonucleotides at high statistical probability
87. RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts
88. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: Ribozyme-mediated reduction of the murine DNA methyltransferase
89. Selecting optimal antisense reagents
90. Anti-sense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides
91. Human gene therapy
92. Gene therapy-promises, problems and prospects
93. Recents developments in the hammerhead ribozyme field
94. Novel non-endocytic delivery of antisense oligonucleotides
95. The delivery of antisense therapeutics
96. Cationic lipids, phosphatidylethanolamine and intracellular delivery of poly-meric, nucleic acid-based drugs
97. Extravasation of macromolecules
98. Gene delivery from a DNA controlled-release stent in porcine coronary arteries
99. Numbering system for the hammerhead